focus -WSS

focus

author：leisure time 2025-10-02 00:30:02 - browse：93

Adam's take main illustration — Molly Ferguson/STAT

It took Anavex Life Sciences seven months to finally acknowledge the failure of a late-stage clinical trial in Rett syndrome.

The negative study outcome was never in doubt, so the only surprise from Tuesday’s announcement was the company’s lame attempt at damage control. Anavex is a serial dissembler of clinical trial results, so I was expecting better spin. Instead, management barely tried, which tells you the real results from the Rett study must be truly awful.

Anavex shares fell 31% to $6 in early trading. The company’s only drug in clinical development, called blarcamesine, is a zero. Rett is the latest failure, following earlier study failures in Alzheimer’s disease and Parkinson’s disease. Yet even with Tuesday’s drop in share price, Anavex still carries a fully diluted market value of nearly $650 million.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： At least 13 dead in Texas as scorching temps continue
Next article： Overprescribed: High cost isn't America's only drug problem

focus

WSS

U.K. decision on ALS drug has neurologists, advocates up in arms

People with mental disorders often marry others with same

Mass General Brigham physicians react to latest merger step

What affirmative action's end means to a medical student

Being 'nonadherent' patient made me a more empathetic doctor

UnitedHealth, in a surprise, takes aim at Steward’s physician group

Wikipedia

focus

knowledge

As demand for Covid shots wanes, Moderna seeks its next success

Gut bacteria may contribute to kidney autoimmunity, study finds

Wildfire smoke exposes gaps in outdoor worker protections

Lupron, used to halt puberty in children, may cause lasting health problems

Medical records are filled with copy

Insurer loopholes limit power of law against surprise medical bills

As demand for Covid shots wanes, Moderna seeks its next success

First Opinion on colorectal cancer screening: letter and response

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Grandmother of French teen shot dead by police officer pleads with rioters to stop the violence

explore

Dexcom's push to bring CGM to type 2 diabetes patients

Fatty liver disease was alleviated by Lilly’s ‘triple

Oral obesity drug from Viking Therapeutics hits key early target

Hundreds died while taking an arthritis drug, but nobody alerted patients

Covid silver lining: Unprecedented look at human immune system

Drug cartel violence flares in western Mexico after vigilante leader's killing

explore

focus

entertainment

explore